A week after the announcement of the death of the fifth patient implanted with the artificial heart, the CEO of Carmat looks back on the epic of this medical revolution.
“Our wish is to be able to include a few patients in the next quarter. »The announcement made to Why actor comes from Stéphane Piat, CEO of Carmat. A few days after the death of the fifth implanted patient, and the suspension of the pivotal trial by the National Medicines Safety Agency, Stéphane Piat discussed the lessons of the Carmat heart adventure. The company designed and developed the first bioprotethical artificial heart with Prof. Alain Carpentier.
The patient, whose death was confirmed on November 30 by Carmat, was the first in the pivotal trial which should include a total of twenty people with end-stage heart failure. The reasons for this death have not yet been communicated. Asked about this, Stéphane Piat explains: “Our analyzes, of which we are 99.99% sure, indicate that the pump is out of the question.” The general manager will not say more, stressing that the patient’s family will be the first to be informed of the final conclusions.
Listen to the interview of Stéphane Piat (Carmat):
This November 15, Carmat requested the resumption of the pivotal study from the ANSM. No answer for the moment. “We are impatiently awaiting his report in order to be able to respond to it and, hopefully, resume the clinical study as soon as possible,” underlines Stéphane Piat. At the microphone of Why actor, the CEO spoke about his vision for the future of the artificial heart. Within 10 years, the prosthesis could become the first option for patients waiting for a transplant, hopes Stéphane Piat.
.
